Fig. 2: Overall survival (OS) in patients with SM stratified by CD2 and CD25 expression patterns in MC. | Leukemia

Fig. 2: Overall survival (OS) in patients with SM stratified by CD2 and CD25 expression patterns in MC.

From: Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Fig. 2

OS was analyzed in a univariate analysis in 1183 patients with SM in whom FU and survival data were reported and results by flow cytometry and/or immunohistochemistry for CD2 expression and CD25 expression on/in MC were available. Four groups of patients were examined based on the pattern of CD2 and CD25 expression on/in MC: CD2-/CD25+ MC, CD2+/CD25+ MC, CD2+/CD25- MC; and CD2-/CD25- MC. The probability of OS in these 4 groups of patients was determined according to the method of Kaplan and Meier. Patients with CD2-negative MC expressing CD25 had a significantly reduced OS compared to patients with MC expressing both, CD2 and CD25. Patients with CD2-negative MC had a significantly shorter OS compared to patients in whom MC expressed CD2 without co-expressing CD25 (p < 0.0001). The p value refers to the comparison of all survival curves as assessed by log-rank test. SM systemic mastocytosis, FU follow-up, MC mast cells.

Back to article page